stockrowAMNEAL PHARMACEUTICALS, INC.
AMRX Healthcare Drug Manufacturers Specialty & Generic
AMNEAL PHARMACEUTICALS, INC.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 billion, up 8.05% from fiscal 2024.
- Revenue
- +9.96%
- EPS
- +267.0%
- Free cash flow
- −50.9%
- Total debt
- +23.8%
Quarter to September 2026, against a year earlier
Follow AMRX
Alert me
AMNEAL PHARMACEUTICALS, INC. (AMRX) Total debt
AMNEAL PHARMACEUTICALS, INC.'s total debt at the end of fiscal 2025 was $2.6B, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $3.2B. Over the past ten years it has ranged from $424.6M (fiscal 2015) to $2.9B (fiscal 2020); the current reading is higher than 45% of that period. AMNEAL PHARMACEUTICALS, INC. ranks 7th of 84 Drug Manufacturers Specialty & Generic companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $2.6B | 3.30% |
| FY2024 | $2.5B | (3.70%) |
| FY2023 | $2.6B | (2.98%) |
| FY2022 | $2.7B | (0.98%) |
| FY2021 | $2.7B | (4.43%) |
| FY2020 | $2.9B | 6.84% |
| FY2019 | $2.7B | 0.03% |
| FY2018 | $2.7B | 81.29% |
| FY2017 | $1.5B | 78.58% |
| FY2016 | $831.3M | 95.78% |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $3.2B | 19.28% |
| Jun 2026 | $2.7B | 1.66% |
| Mar 2026 | $2.6B | 2.13% |
| Dec 2025 | $2.6B | (0.07%) |
| 43 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| ELAN Elanco Animal Health Incorporated compare | $3.9B |
| AMRX AMNEAL PHARMACEUTICALS, INC. | $3.2B |
| ALKS Alkermes plc compare | $1.5B |
| HIMS Hims & Hers Health, Inc. compare | $1.4B |
| RDY Dr. Reddy's Laboratories Ltd compare | $753.0M |
| LNTH Lantheus Holdings, Inc. compare | $571.7M |
| SUPN Indivior Pharmaceuticals Inc. compare | $488.0M |
| LQDA Liquidia Corporation compare | $176.1M |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $13.0M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on AMRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement